# Anthony Barnett

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/anthony-barnett/

## Facts

| Field | Value |
| --- | --- |
| Citations | 39,441 |
| Field | Diabetes Treatment and Management |
| h-index | 89 |
| i10-index | 335 |
| Last Known Institution | Australian Catholic University |
| OpenAlex ID | https://openalex.org/A5023295361 |
| ORCID iD | https://orcid.org/0000-0002-6320-4073 |
| Works | 626 |

## Researcher papers

- [Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019](https://scholariq.org/papers/estimation-of-the-global-prevalence-of-dementia-in-2019-and-forecasted/)
- [A genome-wide search for human type 1 diabetes susceptibility genes](https://scholariq.org/papers/a-genome-wide-search-for-human-type-1-diabetes-susceptibility-genes/)
- [Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility](https://scholariq.org/papers/genome-wide-trans-ancestry-meta-analysis-provides-insight-into-the-genetic/)
- [Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and Nephropathy](https://scholariq.org/papers/angiotensin-receptor-blockade-versus-converting-enzyme-inhibition-in-type-2/)
- [Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus](https://scholariq.org/papers/susceptibility-to-human-type-1-diabetes-at-iddm2-is-determined-by-tandem-repeat/)
- [Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/efficacy-and-safety-of-empagliflozin-added-to-existing-antidiabetes-treatment-in/)
- [Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study](https://scholariq.org/papers/once-weekly-albiglutide-versus-once-daily-liraglutide-in-patients-with-type-2/)
- [Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM2·5 air pollution, 1990–2019: an analysis of data from the Global Burden of Disease Study 2019](https://scholariq.org/papers/estimates-trends-and-drivers-of-the-global-burden-of-type-2-diabetes/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Diabetes and associated disorders](https://scholariq.org/topics/diabetes-and-associated-disorders/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Urban Transport and Accessibility](https://scholariq.org/topics/urban-transport-and-accessibility-2/)

## Researcher university

- [Australian Catholic University](https://scholariq.org/institutions/australian-catholic-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.